SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019:ehz486. https://doi.org/10.1093/eurheartj/ehz486.

  2. 2.

    Eurich DT, McAlister FA. Wrongfully accused: metformin use in heart failure. Expert Rev Cardiovasc Ther. 2011 Feb;9(2):147–50.

    CAS  Article  Google Scholar 

  3. 3.

    Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011 Jan;4(1):53–8.

    CAS  Article  Google Scholar 

  4. 4.

    Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, Greevy RA Jr, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA. 2019 Sep;19:1–11. https://doi.org/10.1001/jama.2019.13206.

    CAS  Article  Google Scholar 

  5. 5.

    Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. IJEM. 2020;24(1):1–122.

    Google Scholar 

  6. 6.

    Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–92. https://doi.org/10.1007/s00125-013-3039-1.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Anil Pareek.

Ethics declarations

Conflict of interest

Authors are employees of Ipca Laboratories Limited which markets anti-diabetic drugs

Research involving human participants and/or animals

This manuscript did not involve participation of human volunteers or animal as this is a letter to the editor (comment on the guideline)

Informed consent

This manuscript did not require participation of humans and hence informed consent was not required as this is a letter to the editor (comment on the guideline)

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pareek, A., Mehta, R.T. & Dharmadhikari, S. SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications. Int J Diabetes Dev Ctries (2020). https://doi.org/10.1007/s13410-020-00833-4

Download citation